VJOncology is committed to improving our service to you

ASCO 2020 | FIH study of ARV-110 in metastatic castrate-resistant prostate cancer

VJOncology is committed to improving our service to you

Sunandana Chandra

Sunandana Chandra, MD, MS, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discusses data from a first in human study of ARV-110, an androgen receptor PROTAC degrader in patients with metastatic castrate-resistant prostate cancer following enzalutamide and/or abiraterone. The study showed an acceptable safety profile and clinical activity in these patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter